Clinical value of antibody D5F3 and Survivin in non small cell lung cancer
10.3969/j.issn.1005-1678.2017.04.139
- VernacularTitle:抗体D5F3及Survivin在非小细胞肺癌患者中的临床应用价值
- Author:
Shaofeng YE
;
Zhaoyang XU
;
Ming WU
- Keywords:
D5F3;
non small cell lung cancer;
clinical application value;
EML4-ALK;
Survivin
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):422-425
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical value of antibody D5F3 and Survivin in patients with non small cell lung cancer.Methods 200 paraffin embedded specimens of patients with non small cell lung cancer tested by RT-PCR(including EML4-ALK mutant and wild type)from October 2012 to June 2014 were selected.The gene protein expression were tested by ALK new antibody D5F3 and the sensitivity and specificity were compared by negative and positive(+～3+).ResultsTest results show(+)the coincidence rate is 15.78％,(+ +)the coincidence rate is 27.27％and(+ + +)compliance rate was 87.5％,the difference was statistically significant(P<0.05).The expression of Survivin protein in NSCLC tissues was correlated with clinicopathological features.The positive rate of Survivin protein expression was correlated with the degree of differentiation(P<0.05),but not with other clinical and pathological features,with the decrease of differentiation,the positive rate of Survivin protein expression was significantly increased.Conclusion D5F3 and Survivin antibodies are highly sensitive and specific in patients with NSCLC,with the screening value,save social resources,for the majority of patients with lung cancer services.
